We then generated a multiple-myeloma cell-line, MM1.S, stably expressing AGIA-AirID-CRBN and compared the enrichment of biotinylated proteins or peptides across two conventional methods (streptavidin or anti-biotin antibody28,29) and tamavidin 2-REV. This evidence concerns the gene CRBN and plasma cell myeloma.